Litcius/Paper detail

Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates

Jihyun Seong, Kyobum Kim

2022Pharmaceutics14 citationsDOIOpen Access PDF

Abstract

Tumor cell lysates (TCLs) are a good immunogenic source of tumor-associated antigens. Since whole necrotic TCLs can enhance the maturation and antigen-presenting ability of dendritic cells (DCs), multiple strategies for the exogenous delivery of TCLs have been investigated as novel cancer immunotherapeutic solutions. The TCL-mediated induction of DC maturation and the subsequent immunological response could be improved by utilizing various material-based carriers. Enhanced antitumor immunity and cancer vaccination efficacy could be eventually achieved through the in vivo administration of TCLs. Therefore, (1) important engineering methodologies to prepare antigen-containing TCLs, (2) current therapeutic approaches using TCL-mediated DC activation, and (3) the significant sequential mechanism of DC-based signaling and stimulation in adaptive immunity are summarized in this review. More importantly, the recently reported developments in biomaterial-based exogenous TCL delivery platforms and co-delivery strategies with adjuvants for effective cancer vaccination and antitumor effects are emphasized.

Topics & Concepts

Acquired immune systemImmune systemAntigenImmunityDendritic cellVaccinationImmunologyIn vivoImmunotherapyCancer researchCancer immunotherapyT cellBiologyBiotechnologyImmunotherapy and Immune ResponsesRNA Interference and Gene DeliveryImmune Cell Function and Interaction
Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates | Litcius